材料科学
磷脂酰丝氨酸
纳米技术
骨质疏松症
药理学
医学
内科学
膜
化学
磷脂
生物化学
作者
Minjee Kang,Zhi Li,Insoon Chang,Changlu Xu,Michelle Chiang,Lauren Kim,Yutong Wu,Jiabing Fan,Tara Aghaloo,Min Lee
标识
DOI:10.1002/adfm.202402521
摘要
Abstract Exosomes derived from mesenchymal stem cells are an active area of research due to their therapeutic potential in treating osteoporosis. To further harness their therapeutic performance in modulating bone resorption, equipped exosomes with osteoclast‐targeting moieties on their surface as well as chemokine receptor antagonists blocking osteoclast recruitment. Phosphatidylserine (PS), a membrane lipid exerting immunosuppressive and phagocytic signals, is incorporated in the membrane of exosome mimetics (EMs) to achieve a marked affinity for osteoclast precursors and potential anti‐resorptive effects. This is also aimed to tackle a CXCL9‐CXCR3 ligand‐receptor axis, a critical signaling axis in regulating osteoclast precursor recruitment and differentiation at bone resorption sites, by encapsulating a chemical antagonist of CXCR3, AMG487, in the PS‐incorporated EMs (PS‐EMs). The osteoclast‐targeting PS‐EMs loaded with AMG487 effectively protected against bone loss in an ovariectomized mouse model. These findings demonstrate the great promise of PS‐EMs as anti‐resorptive nanotherapies for alleviating osteoporosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI